 |
|
|
|||||
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with Novo Nordisk's drug pipeline have contributed to a significant share price decline.
Category:
News and Media
Stress and anxiety among those with debts remains high but help is available, a major survey finds.
Category:
News and Media
Nissan announced this week that it would lay off another 11,000 workers and shut seven factories.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||